Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine

Jinkyung Ko1, Gary A Splitter

  • 1Laboratory of Cellular and Molecular Immunology, Department of Animal Health and Biomedical Sciences, University of Wisconsin, Madison, Wisconsin 53706, USA.

Clinical Microbiology Reviews
|January 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aneuploidy rates and clinical outcomes in vitrified-warmed blastocyst transfer cycles: comparison of biopsy at fresh blastocyst versus vitrified-warmed blastocyst.

Clinical and experimental reproductive medicine·2025
Same author

Brucella suppress STING expression via miR-24 to enhance infection.

PLoS pathogens·2020
Same author

Hepatic and splenic immune response during acute vs. chronic Brucella melitensis infection using in situ microscopy.

Comparative immunology, microbiology and infectious diseases·2020
Same author

Brucella Peptide Cross-Reactive Major Histocompatibility Complex Class I Presentation Activates SIINFEKL-Specific T Cell Receptor-Expressing T Cells.

Infection and immunity·2018
Same author

The Bacterial Second Messenger Cyclic di-GMP Regulates Brucella Pathogenesis and Leads to Altered Host Immune Response.

Infection and immunity·2016
Same author

CD8+ T cell exhaustion, suppressed gamma interferon production, and delayed memory response induced by chronic Brucella melitensis infection.

Infection and immunity·2015

Brucellosis is a zoonotic disease impacting agriculture and human health. Current vaccines have safety concerns, necessitating the development of genetically defined, effective Brucella vaccines for better control.

Area of Science:

  • Veterinary immunology
  • Zoonotic disease research
  • Vaccine development

Background:

  • Brucellosis, caused by Brucella spp., is a significant zoonotic disease with substantial economic impact on agriculture and public health concerns, including its classification as a bioterrorist agent.
  • Existing vaccines like Brucella abortus RB51 and Brucella melitensis REV.1, while used in livestock, present safety and efficacy issues, including abortion and persistent infections, highlighting the need for improved alternatives.
  • The lack of cross-protection among Brucella species complicates vaccine development efforts.

Purpose of the Study:

  • To review current knowledge on Brucella pathogenesis and host immunity.
  • To outline criteria for developing genetically defined and efficient Brucella vaccine strains.
  • To postulate future research directions for understanding Brucella pathogenesis and host immunity to aid vaccine development.

Related Experiment Videos

Main Methods:

  • This is a review article, synthesizing existing research on Brucella pathogenesis, host immune responses, and vaccine development.
  • It analyzes the limitations of current Brucella vaccines.
  • It discusses the requirements for effective Brucella vaccine strains.

Main Results:

  • Current Brucella vaccines (e.g., RB51, REV.1) are genetically undefined and pose risks such as abortion and persistent infection.
  • The REV.1 vaccine exhibits significant virulence and instability, underscoring the urgent need for safer and more effective Brucella melitensis vaccines.
  • Cross-protection against different Brucella species is inconsistent, hindering broad vaccine efficacy.

Conclusions:

  • Genetically defined vaccine strains are crucial for improving the safety and efficacy of Brucellosis control strategies.
  • Further research into Brucella pathogenesis and host immunity is essential for developing next-generation vaccines.
  • Addressing the limitations of current vaccines will significantly impact the prevention of brucellosis in both animals and humans.